HPV Vaccine Cuts Cervical Cancer Deaths in UK Teens
A study published in The Lancet indicates that the HPV vaccine has led to a significant decline in cervical cancer deaths among women in England who were vaccinated between the ages of 12 and 18. Researchers observed an 80 percent drop in mortality for the 20-24 age group between 2015 and 2019, with no recorded deaths in that cohort from 2020 to 2024.
Why it matters
The findings provide strong evidence for the efficacy of national HPV vaccination programs in preventing cancer-related mortality, supporting public health policies globally.
High-income countries that initiated widespread administration of the Human Papilloma Virus (HPV) vaccine in the mid-2000s have experienced substantial declines in cervical cancer cases, marking a significant achievement in medicine. A new study in The Lancet by researchers at Queen Mary University of London (Queen Mary) suggests this vaccine may also be responsible for a near-complete protective effect against death from cervical cancer among women under 30 in England who received the vaccine between 12-18 years old - one of few analyses of the HPV vaccine's effect on mortality.
The article summarizes medical research findings and includes expert commentary on the study's limitations.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in